Background: Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME. Methods: We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid. Results: Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN. Conclusions: First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.
Background/Objectives: Diabetic macular edema is caused by disruptions in the blood–retinal barrier, resulting in leakage and inflammation, appearing in optical coherence tomography as retinal fluid, hard exudates, and hyper-reflective foci. This study aimed to assess volumetric changes in hyper-reflective foci and hard exudates in faricimab-treated diabetic macular edema in real-world practice. Methods: This retrospective longitudinal study included forty-four eyes with faricimab-treated diabetic macular edema and follow-up of ≥40 weeks. Optical coherence tomography scans were analyzed at baseline, post-loading, 6 months and 1 year. Hyper-reflective foci and hard exudates were quantified across macular subfields using a machine-learning algorithm with manual correction. Outcomes included volumetric changes, best-corrected visual acuity, and central subfield thickness. Early morphologic responders were defined post-loading by ≥20% central subfield thickness reduction and/or central subfield thickness below 280 µm. Results: At 1 year, hyper-reflective foci and hard exudate volumes significantly decreased in the central subfield (median differences: −0.025 nL, p = 0.00028; −0.119 nL, p = 0.00025) and outer ring (−0.178 nL, p = 0.00041; −0.612 nL, p = 0.014). Hard exudate volume significantly decreased in the inner ring (−0.740 nL, p < 0.0001). Best-corrected visual acuity and central subfield thickness improved significantly (−0.10 logarithm of the minimum angle of resolution (logMAR), p = 0.0018; −48 µm, p < 0.0001). Total hyper-reflective foci volumes were similar between responders and non-responders. In contrast, hard exudate burden remained numerically higher in non-responders. Conclusions: During the year following the switch to faricimab, HRF and HE burden decreased alongside visual and anatomical improvement. HRF volumes were descriptively similar between early CST responders and non-responders, whereas HE burden remained numerically higher in non-responders.
Purpose: To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. Methods: This retrospective study at the Medical University of Vienna included patients with DME who were switched from aflibercept 2 mg to faricimab. IRF dynamics and central subfield thickness (CST) were assessed after two faricimab injections. Eyes were categorized as prior responders or non‐responders based on their anatomical response to the last aflibercept injection (≥20% CST reduction or CST ≤250 μm). Optical coherence tomography (OCT)–derived CST and quantitative IRF volumes were analysed at baseline and after two faricimab injections. Associations between CST and IRF changes were evaluated. Results: Fifty‐eight eyes of 45 patients (mean age 65.3 ± 10 years) were included, with 56 eyes previously treated with aflibercept. After two faricimab injections (mean follow‐up 10.1 ± 2.2 weeks), CST and total IRF volume decreased significantly ( p < 0.0001). CST reduction was strongly associated with IRF reduction in the central millimetre (estimate 1.00 [0.73–1.28], p < 0.0001), but less so with total IRF volume (estimate 0.22 [0.17–0.28], p < 0.0001). Responders ( n = 28) showed greater CST reduction compared to non‐responders (−105.6 ± 123.9 μm vs. −27.3 ± 60.1 μm; p = 0.0003) and lower total IRF volume after treatment ( p = 0.029), with more consistent regional improvements. Non‐responders showed smaller but still significant IRF reductions. Conclusions: Switching from aflibercept 2 mg to faricimab resulted in significant reductions in CST and IRF volumes after two injections with a more pronounced effect in previous responders. While CST closely reflected central changes, its weaker association with total IRF reduction indicates that quantitative fluid assessment may further refine evaluation of treatment response and retreatment decisions.